Which Anti-CD20 Antibody Is Better in Follicular Lymphoma?
Mené sur 1 202 patients atteints d'un lymphome folliculaire de stade avancé, cet essai randomisé compare l'efficacité, du point de vue de la survie sans progression, et la toxicité du rituximab et de l'obinutuzumab, un anticorps monoclonal anti-CD20 de type 2 modifié par glyco-ingénierie, en traitement de première ligne
Rituximab changed the treatment of patients with follicular lymphoma. When added to standard chemotherapy regimens, it increased the response rate and the complete remission rate.1,2 Rituximab has often been administered as maintenance therapy after a remission that was induced either by single-agent rituximab or by rituximab combined with standard chemotherapy drugs, and it has been shown to prolong the duration of remission.3,4 Since 2000, when rituximab became widely available, survival among patients with low-grade follicular lymphoma has increased from a median of approximately 10 years to a median of approximately 15 to 20 years.
New England Journal of Medicine , éditorial, 2016